Lupus & antiphospholipid syndrome
BCMA-targeted chimeric antigen receptor (CAR) T cell therapy can effectively induce disease remission in refractory lupus nephritis
Authors' conclusion
Anti-BCMA CAR T therapy can help LN patients inducing and maintaining disease remission status safely and effectively
Study context
- Population
- Biopsy-confirmed refractory lupus nephritis (LN)median follow-up 9 months
- Participants
- 7 participants
- Outcome
- Safe dosage of single infusion and occurrence of adverse events
Methodological detailsopen-label
- Open-label
Main finding
As reported in the abstract
Adverse events
- Immune effector cell-associated neurotoxicity syndrome or severe infection
- 0
Secondary outcomes
SLEDAI-2K score · baseline to last follow-up
- SLEDAI-2K at baseline, median (range)
- 18 (range 10-22)
- SLEDAI-2K at last follow-up, median (range)
- 0 (range 0-4)
- Median follow-up of 9 months
DORIS complete remission · last follow-up
- Patients achieving DORIS complete remission
- 5 out of 7
Peripheral B cells
- Effectively eliminated within the first month postinfusions and restored within 3 months except one patient
Renal biopsy and transcriptomic analyses
- Decreased immune complex deposition, reduced clonal abundance and alleviated proinflammatory status of peripheral lymphocytes
Safety
Cytokine release syndrome and other adverse events
- Immune effector cell-associated neurotoxicity syndrome or severe infection
- 0
- Grade 1 cytokine release syndrome
- Hypogammaglobulinemia frequently observed
Original publication
BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann Rheum Dis. Published 18 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →